Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebentafusp +/- Durvalumab/Tremelimumab in Advanced Melanoma
NCT02535078Phase 2Withdrawn
- Sponsor
- Immunocore
- Start
- Nov 2015
- Primary completion
- Jun 2023
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tebentafusp in cutaneous melanoma (CM), sponsored by Immunocore. Planned start Nov 2015; status: withdrawn.
02
Drugs
tebentafusp
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT02535078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535078.